Evaluation of the utility of the sFlt-1/PlGF ratio in pregnancy complicated by pre-eclampsia — single-center study. Preliminary analysis
, 1, 1, 1, 1, 1
Abstract
Objectives: To evaluate relationship between sFlt-1/PlGF ratio, clinical characteristics and outcomes of pre-eclampsia.
Material and methods: Retrospective analysis of 29 pregnant women with pre-eclampsia who had measured sFlt-1/PlGF ratio was conducted using electronic medical records from Obstetrics and Perinatology ward of University Hospital in Cracow.
Results: Women median age: 33.5 years, number of pregnancies: one 52%, two 15%, three 18%,more than three 15%, number of deliveries: one 59.3%, two 37%, three 3.7%, median body mass index during hospitalization: 29.4 kg/m2. Chronic diseases apart from hypertension: 67% of women (diabetes 37%, hypothyroidism 26%, obesity 11%). Median newborns birth weight: 1640 g, median Apgar score at 5 minutes: 8, median umbilical cord blood pH: 7.32. Fetal growth restriction: 28.6% of cases. All deliveries were by c-section. Median gestational age at delivery: 32 weeks. sFlt-1/PlGF ratio was inversely correlated with gestational age at delivery (r = –0.42, p = 0.02). The median sFlt-1/PlGF ratio was higher in women with severe pre-eclampsia (n = 15) than in those with mild pre-eclampsia (n = 14) (211 vs. 57, p < 0.001). sFlt-1/PlGF ratio of > 85 had a sensitivity of 80% and a specificity of 71% for predicting severe pre-eclampsia.
Conclusions: sFlt-1/PlGF ratio is useful in assessing the severity and prognosis of pre-eclampsia. sFlt-1/PlGF ratio should not be used as a sole criterion for making clinical decisions, but as an adjunct to other clinical and laboratory parameters.
Keywords: pre-eclampsiaeclampsiaclinical laboratory testsFLT-1 proteinplacenta growth factor
References
- Tataru-Copos AF, Popescu MI, Murvai R, et al. Efficiency of sFlt-1/PlGF Ratio in Preeclampsia Diagnosis. Medicina (Kaunas). 2022; 58(9).
- Rana S, Lemoine E, Granger JP, et al. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019; 124(7): 1094–1112.
- Stepan H, Galindo A, Hund M, et al. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2023; 61(2): 168–180.
- Verlohren S, Brennecke SP, Galindo A, et al. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022; 27: 42–50.
- Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1): 13–22.
- Kumar N, Das V, Agarwal A, et al. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population. AJOG Glob Rep. 2023; 3(2): 100177.
- Prejbisz A, Dobrowolski P, Kosiński P, et al. Management of hypertension in pregnancy: prevention, diagnosis, treatment and long‑term prognosis. Kardiol Pol. 2019; 77(7-8): 757–806.
- Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012; 206(1): 58.e1–58.e8.
- Lecarpentier E, Tsatsaris V. Angiogenic balance (sFlt-1/PlGF) and preeclampsia. Ann Endocrinol (Paris). 2016; 77(2): 97–100.
- Jeon HR, Jeong DH, Lee Y, et al. sFlt-1/PlGF ratio as a predictive and prognostic marker for preeclampsia. J Obstet Gynaecol Res. 2021; 47(7): 2318–2323.
- Bednarek-Jędrzejek M, Kwiatkowski S, Ksel-Hryciów J, et al. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes. J Perinat Med. 2019; 47(7): 732–740.
- Valenzuela FJ, Pérez-Sepúlveda A, Torres MJ, et al. Pathogenesis of preeclampsia: the genetic component. J Pregnancy. 2012; 2012: 632732.
- Skjaerven R, Vatten LJ, Wilcox AJ, et al. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ. 2005; 331(7521): 877.
- Sun Y, Meng C, Yu L. Correlation of Serum IGF-1 and sFlt-1 Levels with Adverse Pregnancy Outcomes in Patients with Severe Preeclampsia. Altern Ther Health Med. 2023; 29(5): 364–369.
- Nóbrega L, Katz L, Lippo L, et al. Association of sFlt-1 and C-reactive protein with outcomes in severe preeclampsia: A cohort study. Medicine (Baltimore). 2022; 101(11).
- Graupner O, Lobmaier SM, Ortiz JU, et al. sFlt-1/PlGF ratio for the prediction of the time of delivery. Arch Gynecol Obstet. 2018; 298(3): 567–577.
- Burwick RM, Rodriguez MH. Angiogenic Biomarkers in Preeclampsia. Obstet Gynecol. 2024; 143(4): 515–523.
